Quote:

---

"The Company is currently completing the enrollment of its LP-002 clinical study, and based on the interim data will likely increase the number of subjects entered in the study in order to properly power certain key data aspects that were emerging in the interim data set and may add significant value to LymPro on a near-term basis. We are on track to announce full data sets for LymPro later this quarter; We intend to initiate the CLIA certification process for LymPro in the very immediate future at our prospective partner’s laboratory. The initial 12-week process is designed to prepare the analytical performance package (APP) that will be the basis of LymPro’s utility going forward. We project a partnership agreement for LymPro will follow shortly after the completion of the LP-002 study, and the Company is weighing strategic options which include a potential ‘spin-out’ of our diagnostics division (which includes LymPro and NuroPro); We expect significant announcements to begin regarding our mid-clinical stage therapeutic program Eltoprazine, including the initiation of our 200 patient Phase 2b clinical trial for Parkinson’s disease Levadopa-Induced Dyskinesia (PD-LID) "

---